Technical Analysis for CDTX - Cidara Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 2.69 -0.74% -0.02
CDTX closed down 0.74 percent on Tuesday, December 10, 2019, on 1.24 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
See historical CDTX trend table...

Date Alert Name Type % Chg
Stochastic Reached Overbought Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Pocket Pivot Bullish Swing Setup -0.74%
Upper Bollinger Band Walk Strength -0.74%
Above Upper BB Strength -0.74%
Up 3 Days in a Row Strength -0.74%
Up 4 Days in a Row Strength -0.74%
Upper Bollinger Band Walk Strength 1.89%
Above Upper BB Strength 1.89%
Up 3 Days in a Row Strength 1.89%
Older signals for CDTX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases. Its lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of systemic Candida infections. The company also develops CD101 topical, a topical formulation of CD101 for the treatment of recurrent vulvovaginal candidiasis, a prevalent mucosal infection. In addition, it develops a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara Therapeutics is developing its first Cloudbreak development candidate, C001, for the treatment of invasive aspergillosis; and evaluating additional opportunities to expand its Cloudbreak immunotherapy platform to other areas of infectious disease. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is based in San Diego, California.
Biopharmaceutical Medical Specialties Diseases Infectious Diseases Immunotherapy Infectious Disease Anti Infectives Immunotherapy Technology

Is CDTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.3
52 Week Low 1.2225
Average Volume 162,088
200-Day Moving Average 2.03
50-Day Moving Average 2.16
20-Day Moving Average 2.41
10-Day Moving Average 2.48
Average True Range 0.16
ADX 23.56
+DI 30.72
-DI 12.92
Chandelier Exit (Long, 3 ATRs ) 2.33
Chandelier Exit (Short, 3 ATRs ) 2.61
Upper Bollinger Band 2.67
Lower Bollinger Band 2.14
Percent B (%b) 1.03
BandWidth 22.19
MACD Line 0.13
MACD Signal Line 0.10
MACD Histogram 0.0244
Fundamentals Value
Market Cap 45.36 Million
Num Shares 16.9 Million
EPS -3.55
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 0.00
Price-to-Book 2.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.89
Resistance 3 (R3) 2.88 2.81 2.85
Resistance 2 (R2) 2.81 2.76 2.81 2.84
Resistance 1 (R1) 2.75 2.73 2.72 2.76 2.83
Pivot Point 2.68 2.68 2.66 2.68 2.68
Support 1 (S1) 2.62 2.63 2.59 2.63 2.55
Support 2 (S2) 2.55 2.60 2.55 2.54
Support 3 (S3) 2.49 2.55 2.53
Support 4 (S4) 2.50